triazoles has been researched along with selinexor in 198 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 82 (41.41) | 24.3611 |
| 2020's | 116 (58.59) | 2.80 |
| Authors | Studies |
|---|---|
| Apperley, J; Caligiuri, MA; Eisfeld, AK; Ellis, JJ; Ferenchak, G; Gabrail, NY; Garzon, R; Goldman, JM; Harb, JG; Hokland, P; Kauffman, MG; Landesman, Y; Marcucci, G; Milojkovic, D; Neviani, P; Oaks, JJ; Perrotti, D; Reid, A; Roy, DC; Santhanam, R; Shacham, S; Smith, CL; Walker, CJ | 1 |
| Abraham, SA; Holyoake, TL | 1 |
| Andritsos, LA; Beckwith, KA; Byrd, JC; Dubovsky, JA; El-Gamal, D; Flynn, JM; Goettl, VM; Harrington, BK; Jha, S; Jones, JA; Kauffman, M; Lapalombella, R; Maddocks, KJ; McCauley, D; Mo, X; Shacham, S; Williams, KE; Zhong, Y | 1 |
| Chien, W; Ding, L; E-Ling, GL; Hattori, N; Kauffman, M; Koeffler, HP; Lim, SL; Nakamaki, T; Shacham, S; Sudo, M; Sun, H; Sun, Q | 1 |
| Gery, S; Kauffman, M; Koeffler, HP; Shacham, S; Sun, H; Zheng, Y | 1 |
| Chu, K; Friedlander, S; Huso, DL; Landesman, Y; Tan, M; Watnick, T; Weiss, RH; Wettersten, HI | 1 |
| Gerecitano, J | 1 |
| Addis, A; Di Cesare, E; Festuccia, C; Gravina, GL; Kauffman, M; Landesman, Y; Lenzi, A; Mancini, A; McCauley, D; Shacham, S; Tortoreto, M; Zaffaroni, N | 1 |
| Green, AL; Hsu, JH; Hubbell-Engler, B; Jones, K; Knoff, DS; Kung, AL; Ligon, KL; Maire, CL; McCauley, D; Perry, JA; Ramkissoon, LA; Ramkissoon, SH; Shacham, S | 1 |
| Friedlander, S; Kauffman, M; Landesman, Y; Shacham, S; Weiss, RH; Wettersten, HI | 1 |
| Bonneau, K; Bowler, AD; Chenchik, A; Deininger, MW; Eiring, AM; Gantz, KC; Heaton, WL; Iovino, AJ; Kauffman, M; Khorashad, JS; Kraft, IL; Mason, CC; O'Hare, T; Pomicter, AD; Redwine, HM; Reynolds, KR; Shacham, S; Tantravahi, SK; Ullman, KS; Yu, F; Zabriskie, MS | 1 |
| Baloglu, E; Crochiere, M; Daelemans, D; Jacquemyn, M; Landesman, Y; Neggers, JE; Shacham, S; Vanstreels, E; Vercruysse, T | 1 |
| Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X | 1 |
| Beckwith, KA; Byrd, JC; Guinn, D; Hing, ZA; Johnson, AJ; Lapalombella, R; Lehman, AM; Mantel, R; Smith, LL; Williams, E; Williams, K; Woyach, JA | 1 |
| Coppola, D; Crochiere, M; Husain, K; Kashyap, T; Kazim, S; Landesman, Y; Mahipal, A; Malafa, MP; Rashal, T; Sullivan, DM; Zibadi, S | 1 |
| Cominetti, D; De Cesare, M; Deraco, M; Doldi, V; Friedlander, S; Gandellini, P; Kauffman, MG; Landesman, Y; Lopergolo, A; Pennati, M; Shacham, S; Zaffaroni, N | 1 |
| Adamia, S; Berezovskaya, A; Chen, WC; Christie, AL; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Kentsis, A; Klebanov, B; Kung, AL; Landesman, Y; Le, BT; Letai, A; Look, AT; Mansour, MR; Montero, J; Ng, CE; Reed, C; Rodig, SJ; Shacham, S; Stone, RM; Wang, JC | 1 |
| Attiyeh, EF; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Landesman, Y; Lock, R; Lyalin, D; Maris, JM; Reynolds, CP; Shacham, S; Smith, MA; Wu, J | 1 |
| Burke, RT; DeSisto, JA; Landesman, Y; Marcus, JM; Orth, JD | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Bollig-Fischer, A; Dyson, G; Kauffman, M; Landesman, Y; Mohammad, RM; Muqbil, I; Philip, PA; Senapedis, W; Shacham, S; Wu, J | 1 |
| Chan, CH; Cusack, JC; Ferreiro-Neira, I; Hong, TS; Landesman, Y; Liesenfeld, LF; Penson, T; Senapedis, W; Shacham, S; Torres, NE | 1 |
| Festuccia, C; Gravina, GL; Kauffman, M; Landesman, Y; Mancini, A; Marampon, F; McCauley, D; Sanita, P; Shacham, S; Ventura, L; Vitale, F | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Kauffman, M; Kraftson, SJ; Maxwell, SP; Mayampurath, A; McCauley, D; Rosebeck, S; Shacham, S; Volchenboum, SL | 1 |
| Baloglu, E; Crochiere, ML; Del Alamo, D; Donovan, S; Kauffman, M; Klebanov, B; Landesman, Y; Lee, M; Shacham, S | 1 |
| Ambrogio, C; Bombelli, S; Casati, C; Ceccon, M; Chiarle, R; Compagno, M; Di Giacomo, F; Gambacorti-Passerini, C; Giudici, G; Manazza, AD; Mastini, C; Menotti, M; Merlo, MEB; Mologni, L; Poggio, T; Rigolio, R; Turner, SD; Varesio, LM; Voena, C | 1 |
| Anatone, AJ; Czaplinski, JT; Demetri, GD; Fletcher, JA; Nakayama, R; Sicinska, ET; Wagner, AJ; Zhang, YX | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Baloglu, E; Cao, Q; Chu, P; Doan, N; Forscher, C; Gery, S; Guo, X; Koeffler, HP; Lee, VK; Lim, HJ; Lin, DC; Marijon, H; Mayakonda, A; Pang, B; Rajalingam, R; Said, JW; Shacham, S; Sun, H; Thomas, T; Xu, L; Yang, H; Zhao, Z | 1 |
| Mahipal, A; Malafa, M | 1 |
| Baloglu, E; Berezovskaya, A; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Landesman, Y; Look, AT; Senapedis, W; Shacham, S; Stone, RM; Wang, JC | 1 |
| Argueta, C; Bastard, C; Bertrand, P; Bohers, E; Camus, V; Copie-Bergman, C; Cornic, M; Damotte, D; Delarue, R; Dubois, S; Dyer, MJ; Fest, T; Figeac, M; Gaulard, P; Haioun, C; Jais, JP; Jardin, F; Landesman, Y; Lemasle, E; Lemonnier, F; Leroy, K; Maingonnat, C; Mareschal, S; Milpied, N; Moeller, P; Molina, TJ; Ochmann, M; Pelletier, L; Picquenot, JM; Pujals, A; Salles, G; Sola, B; Stamatoullas, A; Sundstrom, C; Tilly, H; Traverse-Glehen, A; Viailly, PJ | 1 |
| Bielski, CM; Boehm, JS; Cheah, JH; Church, AJ; Cima, MJ; Clemons, PA; Cowley, GS; Crompton, BD; Doshi, MB; Garraway, LA; Gill, S; Hahn, WC; Hong, AL; Howell, S; Imamovic, A; Janeway, KA; Jonas, O; Keskula, P; Kryukov, GV; Kynnap, BD; Langer, RS; Meyer, SC; Oh, C; Roberts, CW; Rodriguez-Galindo, C; Root, DE; Schreiber, SL; Shamji, AF; Stegmaier, K; Tseng, YY; Tsherniak, A; van Hummelen, P; Vazquez, F | 1 |
| Bhatnagar, B; Blum, W; Dorrance, AM; Garzon, R; Kashyap, T; Kauffman, M; Lai, TH; Landesman, Y; McNeil, B; Meng, X; Ranganathan, P; Sampath, D; Shacham, S; Yu, X | 1 |
| Abdul Razak, AR; Baker, S; Carlson, R; Condy, M; D'Angelo, SP; Dickson, MA; Ellis, J; Erinjeri, JP; Friedlander, S; Gounder, MM; Gupta, AA; Jasmine, FH; Kauffman, M; Keohan, ML; Loong, HH; Nyquist-Schultz, K; Rashal, T; Saint-Martin, JR; Salah, S; Schwartz, GK; Shacham, S; Tanner, L; Tap, WD; Unger, TJ; Zer, A | 1 |
| Baz, R; Dai, Y; Dalton, WS; Dawson, JL; Grant, S; Kauffman, M; Meads, M; Shacham, S; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J | 1 |
| Aboukameel, A; Argueta, C; Azmi, AS; Drolen, C; Kashyap, T; Kauffman, M; Klebanov, B; Landesman, Y; Lee, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Unger, TJ | 1 |
| Depping, R; von Fallois, M | 1 |
| Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Azmi, AS; Mohammad, RM | 1 |
| Desai, A; Gong, T; Lu, P; Wang, M; Zeng, D; Zhang, K | 1 |
| Baloglu, E; Chien, W; Chuang, LS; Doan, NB; Ganesan, TS; Garg, M; Kanojia, D; Kauffman, M; Koeffler, HP; Mayakonda, A; Said, JW; Shacham, S; Venkatachalam, N | 1 |
| Chen, W; Cui, L; Fang, S; Hou, X; Huang, YY; Li, HQ; Liu, CY; Ouyang, X; Wang, G; Wu, T; Yang, Y; Yu, T; Zhong, Y | 1 |
| Burd, CE; Crochiere, M; Elloul, S; Elnaggar, O; Farren, MR; Hennessey, RC; Kashyap, T; Kendra, K; Klebanov, B; Landesman, Y; Lesinski, GB; Shakya, R; Young, G | 1 |
| Musi, E; Nair, JS; Schwartz, GK | 1 |
| Andreeff, M; Baz, R; Carlson, R; Gabrail, N; Garzon, R; Gutierrez, M; Kashyap, T; Kauffman, M; Klebanov, B; Mau-Sorensen, PM; Rashal, T; Saint-Martin, JR; Savoie, L; Savona, M; Shacham, S; Stone, R; Unger, TJ; Wagner-Johnston, N; Yee, K | 1 |
| Algrin, C; Bougacha, N; Brunelle-Navas, MN; Chapiro, E; Choquet, S; Cosson, A; Cung, HA; Damm, F; Davi, F; Feugier, P; Gabillaud, C; Herbi, L; Keren, B; Lambert, J; Landesman, Y; Le Garff-Tavernier, M; Leblond, V; Lejeune, J; Lepretre, S; Lesty, C; Maloum, K; Merle-Béral, H; Morel, V; Nguyen-Khac, F; Roos-Weil, D; Susin, SA; Sutton, L; Uzunov, M | 1 |
| Burke, RT; Marcus, JM; Orth, JD | 1 |
| Crochiere, M; Italiano, JE; Kashyap, T; Klebanov, B; Landesman, Y; Liu, ZJ; Machlus, KR; Shacham, E; Sola-Visner, M; Soussou, TS; Unger, TJ; Vijey, P; Wu, SK | 1 |
| Akcakanat, A; Arango, NP; Evans, KW; Gonzalez-Angulo, AM; Janku, F; Kim, C; Meric-Bernstam, F; Naing, A; Scott, S; Tripathy, D; Ueno, NT; Yuca, E; Zhao, M | 1 |
| Alberobello, AT; Conforti, F; De Pas, T; Giaccone, G; Guha, U; McCutcheon, JN; Rahhal, R; Rao, G; Rodriguez, JA; Wang, Y; Yonemori, Y; Zhang, X; Zhang, YW | 1 |
| Baloglu, E; Ding, LW; Doan, NB; Ganesan, TS; Garg, M; Kanojia, D; Kauffman, M; Koeffler, HP; Mayakonda, A; Nagare, RP; S, S; Sadhanandhan, B; Said, JW; Shacham, S; Suresh, S | 1 |
| Argueta, C; Carenini, N; Ciusani, E; Corno, C; De Cesare, M; Gatti, L; Landesman, Y; Minoli, L; Perego, P; Scanziani, E; Stamatakos, S; Stucchi, S; Zaffaroni, N | 1 |
| Abrisqueta, P; Bobillo, S; Bosch, F; Carpio, C; Castellví, J; Crespo, M; Raheja, P | 1 |
| Abonour, R; Ahmann, G; Baz, R; Bhutani, D; Chari, A; Choe-Juliak, C; Cole, C; Cornell, RF; Costa, LJ; Dingli, D; Fonseca, R; Hoffman, JE; Huff, CA; Jagannath, S; Jakubowiak, A; Kaminetzky, D; Kauffman, M; Lopez, I; Nooka, A; Parker, TL; Picklesimer, CD; Richter, J; Saint-Martin, JR; Schiller, G; Shacham, S; Siegel, D; Stewart, AK; Van Wier, S; Vij, R; Vogl, DT; Yee, AJ; Zonder, J | 1 |
| Burki, TK | 1 |
| Aggarwal, R; Chang, E; Fong, L; Friedlander, TW; Kim, W; Lin, AM; Louttit, M; Ryan, CJ; Siegel, AP; Wei, XX; Zhang, L | 1 |
| Baloglu, E; Chari, A; Cornell, RF; Gandhi, UH; Senapedis, W; Unger, TJ; Vogl, D | 1 |
| Camphausen, K; O'Neill, JW; Rath, BH; Tofilon, PJ; Wahba, A | 1 |
| Burke, RT; Doak, AE; Marcus, JM; Orth, JD; Park, S | 1 |
| Bai, Z; Chen, T; Feng, Z; Gui, H; Huang, J; Li, G; Li, M; Li, Y; Pan, J; Wang, J; Wu, M; Wu, Y; Xu, H; Zhou, H | 1 |
| Baloglu, E; Koeffler, HP; Padmanabhan, N; Peethala, PC; Shacham, S; Soe, MY; Subhash, VV; Tan, DSP; Tan, P; Tan, SH; Tan, WL; Thuya, WL; Wang, L; Wong, FY; Yeo, MS; Yong, WP | 1 |
| Brunetti, L; Buckley, DL; Falini, B; Gionfriddo, I; Goodell, MA; Gundry, MC; Guzman, AG; Huang, YH; Kornblau, SM; Lin, CY; Martelli, MP; Mezzasoma, F; Milano, F; Nabet, B; Ramabadran, R; Sorcini, D; Sportoletti, P | 1 |
| Aljama, MA; Dingli, D; Sidiqi, MH | 1 |
| Bianchetti, E; Ishida, CT; Karpel-Massler, G; Shang, E; Shu, C; Siegelin, MD; Westhoff, MA; Zhang, Y | 1 |
| Gourd, E | 1 |
| Kadri, S; Landesman, Y; Lee, J; Lu, P; Maltsev, N; Ming, M; Shacham, S; Sharma, S; Sukhanova, M; Wang, W; Wang, YL; Wu, W; Xie, B | 1 |
| Edwards, H; Ge, Y; Lin, H; Liu, S; Luedtke, DA; Su, Y; Taub, JW; Wang, Y | 1 |
| Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E | 1 |
| Boulware, D; Extermann, M; Goodridge, D; Han, HS; Hogue, D; Ismail-Khan, R; Khong, H; Shafique, M; Soliman, H; Sullivan, D | 1 |
| Liu, JW; Xiong, ZQ; Yang, C; Zhao, M; Zhu, ZC | 1 |
| Chari, A; Cole, CE; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Karrison, T; McIver, A; Mikhael, J; Nam, J; Rosebeck, S; Rosenbaum, CA; Severson, E; Stephens, LA; Tinari, K; Turowski, A; Zimmerman, TM; Zonder, JA | 1 |
| Estey, EH; Percival, MM | 1 |
| Dama, P; Fulton, N; Kline, J; Liu, H; Tang, M | 1 |
| Syed, YY | 1 |
| Chang, H; Chari, A; Choquet, S; Cole, C; Comenzo, RL; Cornell, RF; Costa, LJ; Crochiere, M; Delforge, M; Dimopoulos, M; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Frenzel, L; Gavriatopoulou, M; Hoffman, JE; Huff, CA; Illmer, T; Jagannath, S; Kaminetzky, D; Karlin, L; Kauffman, MG; Landesman, Y; Levy, M; Li, L; Lonial, S; Meuleman, N; Mohty, M; Moreau, P; Nooka, AK; Parekh, S; Parker, TL; Perrot, A; Picklesimer, C; Podar, K; Raab, MS; Richardson, PG; Richter, J; Saint-Martin, JR; Schiller, G; Schreder, M; Shacham, S; Shah, J; Stewart, AK; Tang, S; Tuchman, S; Vij, R; Vlummens, P; Vogl, DT; Weisel, KC; Yee, AJ | 1 |
| Stirrups, R | 1 |
| Romero, D | 1 |
| Carrà, G; Guerrasio, A; Morotti, A; Russo, I | 1 |
| Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J | 1 |
| Jhaveri, KD; Wanchoo, R | 1 |
| Chari, A; Jagannath, S; Vogl, DT | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Ben-Barouch, S; Kuruvilla, J | 1 |
| Aladhraei, M; Kassem Al-Thobhani, A; Poungvarin, N; Suwannalert, P | 1 |
| Baz, R; Nishihori, T | 1 |
| Chari, A; Jagannath, S; Podar, K; Richardson, PG; Shah, J | 1 |
| Beaver, LP; Clair, PM; Deininger, MW; Eiring, AM; Hare, TO; Heaton, WL; Mason, CC; Pomicter, AD; Senina, A; Shacham, S; Than, H; Yan, D | 1 |
| Chung, D; Diab, V; Drullinsky, P; Giralt, S; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Mailankody, S; Mastey, D; Salcedo, M; Schlossman, J; Scordo, M; Shah, G; Shah, U; Smith, E; Werner, K | 1 |
| Gill, J; Haslam, A; Prasad, V | 1 |
| Chakraborty, R; Efficace, F | 1 |
| Abonour, R; Bahlis, N; Baz, R; Berdeja, JG; Chai, Y; Chari, A; Chen, C; Choquet, S; Cornell, RF; Dimopoulos, MA; Dingli, D; Gasparetto, C; Gavriatopoulou, M; Hofmeister, CC; Huff, CA; Jagannath, S; Jakubowiak, A; Kauffman, MG; Lentzsch, S; Li, K; Li, L; Lonial, S; Mohty, M; Moreau, P; Nooka, AK; Parker, TL; Reece, D; Richter, J; Shacham, S; Shah, J; Siegel, D; Tuchman, S; Unger, TJ; Vogl, DT; Weisel, KC; White, D; Yee, AJ | 1 |
| Chari, A; DeCastro, A; Jagannath, S; Jakubowiak, A; Jasielec, J; Kauffman, M; Shacham, S; Shah, J; Unger, TJ; Vogl, DT | 1 |
| Chen, J; Chu, H; Chu, P; Gao, J; Lei, Y; Li, G; Li, X; Liang, M; Liu, C; Liu, M; Long, F; Long, X; Sun, Q; Tian, X; Wang, F; Yang, Y | 1 |
| Chari, A; Costa, LJ; Faiman, B; Gleason, C; Jagannath, S; Lentzch, S; Mikhael, J; Nooka, AK; Noonan, KR; Richardson, PG; Siegel, D | 1 |
| Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W | 1 |
| Ahmann, GJ; Bergsagel, PL; Bonolo de Campos, C; Braggio, E; Bruins, LA; Darvish, SA; Dingli, D; Fonseca, R; Henderson, KJ; Kapoor, P; Kruse, JJ; Kumar, SK; Larsen, JT; Lopez Armenta, ID; Meurice, N; Petit, JL; Polito, AN; Reeder, CB; Stewart, AK; Stewart, WM; Tian, S; Wang, P; Wang, X; Zhu, YX | 1 |
| Azizian, NG; Li, Y | 1 |
| Jagannath, S; Richard, S; Richter, J | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Garzon, R; Lapalombella, R; Walker, JS | 1 |
| Chiappella, A; Corradini, P | 1 |
| Bakhshi, S; Bouabdallah, R; Canales, MA; Casasnovas, O; Cavallo, F; Chang, H; Choquet, S; Corona, K; De la Cruz, F; Egyed, M; Follows, G; Goy, A; Gurion, R; Hamad, N; Hill, B; Jaeger, U; Joshi, A; Kalakonda, N; Kauffman, M; Landesman, Y; Ma, X; Maerevoet, M; McCarthy, D; Mishra, S; Offner, F; Saint-Martin, JR; Sancho, JM; Schuster, M; Shacham, S; Shah, J; Thieblemont, C; Van Den Neste, E; Vassilakopoulos, TP; Vermaat, JSP; Wang, H; Warzocha, K; Zijlstra, JM | 1 |
| Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S | 1 |
| Abrisqueta, P; Bobillo, S; Boix, J; Bosch, F; Carabia, J; Castellví, J; Céspedes Torrez, DH; Crespo, M; Escoda, L; Jiménez, I; Martínez-Ricarte, F; Nieto, JC; Pagès, C; Palacio, C; Perla, C; Puigdefàbregas, L; Purroy, N; Seoane, J | 1 |
| Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
| Jhaveri, KD; Kala, J; Mamlouk, O | 1 |
| Dakle, P; Jeitany, M; Jiang, YY; Kanojia, D; Kappei, D; Koeffler, HP; Landesman, Y; Madan, V; Mukundan, V; Pathak, E; Prabhu, A; Tam, WL | 1 |
| Avigdor, A; Geva, M; Magen, H; Nagler, A; Volchik, Y | 1 |
| Benkova, K; Hajek, R; Jelinek, T; Mihalyova, J | 1 |
| Biran, N; Callander, N; Chari, A; Chhabra, S; Cornell, R; Costa, L; Fiala, MA; Gahvari, Z; Gandhi, U; Godby, K; Gupta, R; Hari, P; Jagannath, S; Jagosky, M; Kang, Y; Kansagra, A; Kauffman, M; Kodali, S; Kumar, SK; Lakshman, A; Liedtke, M; Lonial, S; Ma, X; Malek, E; Mansour, J; McGehee, EF; Neppalli, A; Paul, B; Richardson, P; Scott, EC; Shacham, S; Shah, J; Siegel, DS; Tang, S; Umyarova, E; Usmani, SZ; Varnado, W; Vij, R | 1 |
| Gopal, AK; Smith, SD | 1 |
| Kalakonda, N; Kauffman, M; Shah, J | 1 |
| Chari, A; Cho, HJ; DeCastro, A; Jagannath, S; Landesman, Y; Madduri, D; Mouhieddine, TH; Parekh, S; Richter, J; Shah, J | 1 |
| Argueta, C; Croce, A; Daidone, MG; De Marco, C; Figini, M; Frigerio, B; Gianni, AM; Landesman, Y; Martini, S; Pennati, M; Satta, A; Zaffaroni, N | 1 |
| Bauer, AA; Cubitt, CL; Cui, Y; Dalton, WS; Dawson, JL; Gomez, JA; Kim, J; Nishihori, T; Sullivan, DM; Turner, JG | 1 |
| Cardozo-Ojeda, EF; Goyal, A; Schiffer, JT | 1 |
| Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ | 1 |
| Azmi, AS; Mohammad, RM; Uddin, MH | 1 |
| Harris, LJ; Martin, M; Patel, K | 1 |
| Doan, HQ; Gupta, R; Rady, PL; Simonette, RA; Tyring, SK | 1 |
| Abdul Razak, A; Accardi, S; Al-Ezzi, E; Fasih, S; Gupta, A; Lewin, J; Malone, E; Pedersen, P | 1 |
| Bie, Z; Chen, J; Dong, Z; Huang, D; Jiang, R; Jiang, X; Li, L; Li, M; Lin, L; Liu, Z; Meng, Z; Qin, T; Sun, T; Wang, J; Wang, L; Yang, G; Yu, J; Zhang, C; Zhang, M; Zhang, Y | 1 |
| Abeykoon, JP; Boughey, JC; Boysen, J; Carr, RM; Couch, FJ; Dasari, S; Feldman, AL; Goetz, MP; Hou, X; Hu, C; Kapoor, P; King, RL; Kumar, S; Manske, MK; Mladek, AC; Molina, JR; Nowakowski, KE; Paludo, J; Parikh, SA; Patnaik, MM; Phillips, JL; Ravindran, A; Robinson, SI; Sarkaria, JN; Stenson, MJ; Wang, L; Weroha, SJ; Witzig, TE; Wu, X; Yu, J | 1 |
| Abdul Razak, A; Al-Ezzi, E; Bravetti, J; D'Angelo, SP; Gounder, M; Mazzocca, A; Vincenzi, B; Wang, H; Watson, G | 1 |
| Andrei, G; Bittencourt, A; Boons, E; Daelemans, D; Dierckx, T; Farré, L; Jacquemyn, M; Kataoka, K; Landesman, Y; Menezes, SM; Nogueira, TC; Ogawa, S; Snoeck, R; Tamir, S; Van Weyenbergh, J | 1 |
| Dutta, P; Hinton, RB; Kodigepalli, KM; LaHaye, S; Lincoln, J; Nagel, C; Rains, S; Thatcher, K; Thompson, JW | 1 |
| Barisella, M; Brich, S; Casali, PG; Colombo, C; Dagrada, GP; Dei Tos, AP; El Bezawy, R; Gounder, M; Gronchi, A; Lauricella, C; Pasquali, S; Percio, S; Sanfilippo, R; Stacchiotti, S; Tortoreto, M; Zaffaroni, N; Zuco, V | 1 |
| DeMari, S; Hassan, H; Hughes, DM; Sanchorawala, V; Sloan, JM | 1 |
| Ahnert, JR; Al-Zubidi, N; Bernstam, FM; Fu, S; Gombos, DS; Hong, DS; Karp, DD; Naing, A; Piha-Paul, SA; Subbiah, V; Tsimberidou, AM | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Bader, JC; Li, H; Shacham, S; Shah, J; Tang, S; Wada, R; Xu, H | 1 |
| Aboukameel, A; Azmi, AS; Bhutani, D; Chaker, M; Corona, K; Houde, C; Huddlestun, A; Kauffman, M; Khan, HY; Landesman, Y; Li, Y; Mohammad, RM; Muqbil, I; Neveux, C; Pregja, S; Ramchandren, R; Reichel, K; Seymour, EK; Shacham, S; Shah, J; Sterbis, G; Yang, J; Zonder, JA | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, AZ; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hájek, R; Jagannath, S; Jeha, J; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Abdul Razak, AR; Attia, S; Chawla, SP; Chmielowski, B; Gilligan, AM; Gounder, M; Grignani, G; Jones, RL; Kauffman, M; Leong, H; Ma, X; Martin-Broto, J; Riedel, RF; Schuetze, SM; Shacham, S; Shah, J; Somaiah, N; Vincenzi, B; Wagner, AJ | 1 |
| Depping, R; Dunst, J; Kosyna, FK; Landesman, Y; Mandl, M; von Fallois, M | 1 |
| Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M | 1 |
| Li, CF; Qiu, XJ; Wang, HJ; Zhou, CJ; Zhou, CY; Zhu, MJ | 1 |
| Couvertier, S; Feyertag, F; Guckian, K; Huber, KVM; Johnson, DS; Martin, JG; Ward, JA; Zhang, L | 1 |
| Ayers, D; Cope, S; Davies, FE; Delforge, M; Dhanasiri, S; Hege, K; Jansen, JP; Mojebi, A; Rodriguez-Otero, P; Weisel, K | 1 |
| Bean, S; Carter, BW; Colen, R; Gong, J; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Ogbonna, DC; Pant, S; Piha-Paul, SA; Shah, J; Subbiah, V; Thein, KZ; Tsimberidou, A; Zarifa, A | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Delimpasi, S; Dimopoulos, MA; Grosicki, S; Kauffman, MG; Moreau, P; Richardson, PG | 1 |
| Bahlis, NJ; Biran, N; Chari, A; Gasparetto, C; Jagannath, S; Lonial, S; Mo, CC; Nooka, AK; Richardson, P; Siegel, D | 1 |
| Benzel, J; Burhenne, J; Foerster, KI; Haefeli, WE; Pajtler, KW; Pfister, S; Sauter, M | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Chang, H; Chari, A; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Facon, T; Garg, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Landesman, Y; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richard, S; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Gormley, NJ; Kasamon, YL; Li, RJ; Ma, L; Okusanya, OO; Pazdur, R; Price, LSL; Richardson, NC; Theoret, M; Wu, YT | 1 |
| Bar, N; Di, M; Giri, S; Huntington, SF; Parker, T; Patel, KK | 1 |
| Chang, H; Hou, B; Kashyap, T; Kauffman, MG; Landesman, Y; Murray, J; Shacham, S; Tamir, S; Tripp, RA; Walker, CJ | 1 |
| Anderson, LD; Auner, HW; Bahlis, NJ; Beaumont, JL; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Facon, T; Garg, MK; Grosicki, S; Hájek, R; Hudgens, S; Illmer, T; Jagannath, S; Kauffman, M; Kriachok, I; Leleu, X; Leong, H; Levy, M; Ma, X; Pour, L; Quach, H; Richardson, P; Sanchez, L; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Tang, S; Usenko, G; Venner, C; Yu, H | 1 |
| Gong, W; Kleist, C; Müller-Tidow, C; Neuber, B; Ni, M; Sauer, T; Schmitt, A; Schmitt, M; Schubert, ML; Sellner, L; Stock, S; Wang, L; Wang, S; Yao, H | 1 |
| Abid, H; Abid, MB; Wu, JF | 1 |
| Bakhshi, S; Caimi, P; Canales, M; Casasnovas, RO; Cavallo, F; Chamoun, K; Choquet, S; Corona, K; De la Cruz, F; Egyed, M; Follows, G; Goy, A; Gurion, R; Hamad, N; Hill, B; Jaeger, U; Kalakonda, N; Kauffman, MG; Ku, M; Kuruvilla, J; Ma, X; Maerevoet, M; Offner, F; Samal, P; Sancho, JM; Schuster, M; Shacham, S; Shah, J; Thieblemont, C; Van Den Neste, E; Vassilakopoulos, TP; Vermaat, JSP; Warzocha, K; Zijlstra, JM | 1 |
| Dolph, M; Leong, H; Tremblay, G | 1 |
| Castellon, C; Chaquette, R; Meleveedu, KS; Onkarappa Mangala, Y; Perez Rodriguez, A | 1 |
| Bhalla, S; Chari, A; Cho, H; Dhadwal, A; Florendo, E; Jagannath, S; Jiang, G; Lagana, A; Madduri, D; Mancia, IS; Parekh, S; Richter, J; Thomas, J | 1 |
| Green, K; Hashmi, H | 1 |
| Biran, N; Breeze, J; Chari, A; Choquet, S; Cornell, RF; Costa, L; Daniele, P; Delforge, M; Dimopoulos, MA; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Gavriatopoulou, M; Hoffman, JE; Kaminetzky, D; Kauffman, M; Laurent, F; Levy, M; Li, L; Lionel, K; Meuleman, N; Mohty, M; Moreau, P; Nooka, A; Parker, T; Podar, K; Raab, M; Richardson, P; Richter, J; Schiller, G; Schreder, M; Shacham, S; Shah, J; Siegel, D; Sundar, J; Tremblay, G; Tuchman, S; Vij, R; Vlummens, P; Vogl, D; Weisel, K | 1 |
| Bakhshi, S; Caimi, PF; Canales, M; Casasnovas, RO; Cavallo, F; Chamoun, K; Choquet, S; Egyed, M; Follows, G; Goy, A; Gurion, R; Hamad, N; Hill, B; Jaeger, U; Kalakonda, N; Kauffman, MG; Ku, M; Kuruvilla, J; la Cruz, F; Ma, X; Maerevoet, M; Neste, EVD; Offner, F; Samal, P; Sancho, JM; Schuster, M; Shacham, S; Shah, J; Thieblemont, C; Vassilakopoulos, TP; Vermaat, JSP; Warzocha, K; Zijlstra, JM | 1 |
| Ahnert, JR; Albittar, AA; Dalal, S; Dev, R; Fu, S; Hui, D; Karp, DD; Liu, S; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Rubin, L; Tsimberidou, AM; Yap, TA; Zarifa, A; Zhong, LL | 1 |
| Ferrante, SA; Gorsh, B; Hogea, C; Hughes, R; Kapetanakis, V; Popat, R; Prawitz, T; Sarri, G; Suvannasankha, A; Wang, F; Willson, J | 1 |
| Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
| Amero, P; Bayraktar, E; Coleman, RL; Dasari, SK; Glassman, D; Handley, KF; Ivan, C; Joseph, R; Kim, M; Landesman, Y; Ma, S; Nguyen, N; Powell, RT; Ram, PT; Rodriguez-Aguayo, C; Sobieski, M; Sood, AK; Stephan, C; Stur, E; Umamaheswaran, S; Wen, Y; Westin, SN | 1 |
| Christgen, S; Kanneganti, TD; Karki, R; Lee, S; Malireddi, RKS; Neale, G; Nguyen, LN; Samir, P; Sharma, BR; Sundaram, B; Vogel, P; Wang, Y; Zheng, M | 1 |
| Chavez, JC; Logue, JM | 1 |
| Ando, K; Kawada, H; Kitamura, Y; Ogawa, Y; Ogiya, D; Suzuki, R | 1 |
| Ammu, S; Bahlis, NJ; Baljevic, M; Ben-Shahar, O; Bensinger, WI; Bentur, OS; Biran, N; Callander, NS; Chen, CI; DeCastro, A; Gasparetto, C; Kauffman, M; Kotb, R; LeBlanc, R; Lentzsch, S; Lipe, B; Madan, S; Rossi, AC; Schiller, GJ; Sebag, M; Shacham, S; Shah, J; Sutherland, HJ; Tuchman, SA; Van Domelen, D; Venner, CP; White, D; Zhang, C; Zhou, T | 1 |
| Chalopin, T; Nsiala, L | 1 |
| Arazy, M; Auner, HW; Benjamin, R; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Garg, MK; Gavriatopoulou, M; Grosicki, S; Hájek, R; Kauffman, MG; Leleu, X; Levy, Y; Mateos, MV; Moreau, P; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Sinha, DK; Venner, CP | 1 |
| Cui, S; Si, Y; Wang, J; Wang, Y; Yin, X; Yu, L | 1 |
| Li, S; Shi, Y; Xu, S | 1 |
| Bakhshi, S; Caimi, P; Canales, M; Casasnovas, RO; Cavallo, F; Chamoun, K; Choquet, S; Corona, K; De la Cruz, F; Egyed, M; Follows, G; Goy, A; Gurion, R; Hamad, N; Hill, B; Jaeger, U; Kalakonda, N; Kauffman, MG; Ku, M; Kuruvilla, J; Ma, X; Maerevoet, M; Neste, EVD; Offner, F; Samal, P; Sancho, JM; Schuster, M; Shacham, S; Shah, J; Thieblemont, C; Vassilakopoulos, T; Vermaat, JSP; Warzocha, K; Zijlstra, J | 1 |
| Bartley, BR; Doan, HQ; Moore, SA; Narayanan, D; Rady, PL; Simonette, RA; Tyring, SK | 1 |
| Lee, DG; Nguyen, R; Peng, J; Sun, M; Thiele, CJ; Wang, H | 1 |
| Ben Barouch, S; Bhella, S; Crump, M; Kridel, R; Kukreti, V; Kuruvilla, J; Prica, A | 1 |
| Sylvain, C | 1 |
| Chari, A; Costa, LJ; Gasparetto, CJ; Jagannath, S; Lentzsch, S; Mikhael, J; Nooka, AK; Richardson, PG; Siegel, DS | 1 |
| An, G; Cai, Z; Chang, C; Chen, L; Chen, W; Chen, X; Fang, B; Fu, C; Fu, W; Gao, S; Jing, H; Li, F; Liu, J; Liu, Z; Lynch, K; Qiu, L; Wang, A; Wei, Y; Weng, J; Xia, Z; Xiang, W; Yu, Y; Yu, Z | 1 |
| Chen, SL; Chen, XQ; Dai, YJ; Hu, F; Li, XP; Liang, Y; Lu, YX; Wang, DW | 1 |
| Alcindor, T; Attia, S; Badalamenti, G; Ben-Shahar, O; Beveridge, RD; Blay, JY; Burgess, M; Chang, H; Chawla, S; Chen, JL; Chevreau, C; Chmielowski, B; Davis, EJ; Deshpande, H; Dickson, MA; Duffaud, F; Elias, A; Eriksson, M; Forscher, C; Ganjoo, KN; Garcia Del Muro, X; Gonzalez, AE; Götze, K; Gounder, MM; Grignani, G; Gröschel, S; Hartner, L; Hatcher, H; Herráez, AC; Italiano, A; Jones, RL; Kasper, B; Kauffman, MG; Landesman, Y; Lapeire, L; Le Cesne, A; Lee, A; Li, L; Liu, J; Loggers, ET; Martin-Broto, J; Mazzeo, F; Meng, C; Meyer, C; Michel, D; Mulcahy, MF; Napolitano, A; Nicholas, G; Okuno, S; Penel, N; Philip, T; Piperno-Neumann, S; Razak, AA; Reichardt, P; Riedel, RF; Ryan, C; Schuetze, SM; Schwartz, GK; Shacham, S; Shah, JJ; Somaiah, N; Stacchiotti, S; Valverde Morales, CM; Van Domelen, DR; Van Tine, BA; Vincenzi, B; von Mehren, M; Wagner, AJ; Walker, CJ; Yakobson, A; Zick, A | 1 |
| Ben-Shahar, O; Cass, M; Kashyap, T; Landesman, Y; McDonald, AB | 1 |
| Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
| Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA | 1 |
| Ackerstein, A; Aderka, D; Appel, S; Apter, S; Berger, R; Boursi, B; Crochiere, M; Golan, T; Halpern, N; Inbar, Y; Jacobson, G; Khaikin, M; Landesman, Y; Lawrence, YR; Margalit, O; Rashal, T; Raskin, S; Schvimer, M; Shacham, S; Shacham-Shmueli, E; Symon, Z; Venturero, M; Yang, F; Yarom, N | 1 |
| Agte, S; Aleman, A; Bhalla, S; Chari, A; Cho, HJ; Ghodke-Puranik, Y; Jagannath, S; Jiang, J; Laganà, A; Landesman, Y; Leshchenko, V; Madduri, D; Melnekoff, DT; Parekh, S; Restrepo, P; Richard, S; Richter, J; Walker, CJ | 1 |
| Banerjee, A; Berdeja, JG; Deraedt, W; Diels, J; Jackson, CC; Jagannath, S; Krishnan, A; Martin, T; Nesheiwat, T; Schecter, JM; Usmani, SZ; Valluri, S; Van Sanden, S; Vogel, M; Weisel, K; Yalniz, F; Yeh, TM | 1 |
| Garate, GM; Ochoa, PA; Remaggi, G | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
| Goldsmith, SR; Liu, L; Shiah, K | 1 |
| Bartley, BR; Doan, HQ; Landes, JR; Moore, SA; Rady, PL; Tyring, SK | 1 |
| Bekker-Jensen, DB; Blume-Jensen, P; Eguchi, A; Emdal, KB; Itzykson, R; Kazi, JU; Masson, K; Nilsson, H; Olsen, JV; Palacio-Escat, N; Puissant, A; Rönnstrand, L; Saez-Rodriguez, J; Wigerup, C | 1 |
| Cai, C; Dong, P; Gong, W; Li, O; Liu, SL; Pan, LJ; Shu, YJ; Yang, ZY; Zhang, J; Zhao, C | 1 |
| Amenábar, C; Angeli, A; Carta, F; Ferreira, BI; Jimenez, L; Link, W; Machuqueiro, M; Mayoral-Varo, V; Megías, D; Mourato, C; Ortega, J; Sequeira, JGN; Silvestri, R; Supuran, CT | 1 |
| Kong, Y; Li, J; Li, Y; Liang, J; Miao, Y; Pan, B; Qin, S; Tang, J; Wang, L; Wu, J; Xia, Y; Xu, W; Xu, Z; Zhang, X; Zhu, H | 1 |
| Tang, XY; Wang, Y; Xu, RR | 1 |
| Bergamini, A; Cibula, D; Fariñas-Madrid, L; Guerra, EM; Hamilton, EP; Henry, S; Høgdall, E; Kauffman, MG; Klat, J; Levy, T; Makker, V; Martínez-Garcia, J; Michel, D; Miller, DS; Mirza, MR; Monk, BJ; Pérez-Fidalgo, JA; Pothuri, B; Raspagliesi, F; Richardson, DL; Romero, I; Scambia, G; Schochter, F; Sehouli, J; Shacham, S; Slomovitz, B; Valabrega, G; Van Gorp, T; Vergote, I; Welch, S; Wimberger, P | 1 |
| Day, D; Eliason, A; Hansen, AR; Hernando-Calvo, A; Jennings, S; Malone, E; Prawira, A; Rodriguez, A; Siu, LL; Spreafico, A; Wang, L; Weinreb, I; Wong, H; Yang, SYC | 1 |
| Gouda, MA; Thein, KZ | 1 |
26 review(s) available for triazoles and selinexor
| Article | Year |
|---|---|
Importins and exportins as therapeutic targets in cancer.
Topics: Active Transport, Cell Nucleus; Animals; Cell Nucleus; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Neoplasms; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triazoles | 2016 |
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Boron Compounds; Congresses as Topic; Glycine; Humans; Hydrazines; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Thiadiazoles; Treatment Outcome; Triazoles | 2017 |
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles | 2018 |
Therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Decision Making; Gene Expression Profiling; Humans; Hydrazines; Immunotherapy; In Situ Hybridization, Fluorescence; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Sulfonamides; Symptom Assessment; Transplantation, Autologous; Triazoles; Watchful Waiting | 2018 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Selinexor: First Global Approval.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2019 |
Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy.
Topics: Apoptosis; Cell Nucleus; Cytoplasm; Cytosol; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Export Signals; Nuclear Localization Signals; Receptors, Cytoplasmic and Nuclear; Triazoles | 2019 |
Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Biomarkers, Tumor; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Triazoles | 2020 |
Selinexor for the treatment of multiple myeloma.
Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Clinical Trials as Topic; Dexamethasone; Drug Evaluation, Preclinical; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Prognosis; Receptors, Cytoplasmic and Nuclear; Triazoles | 2020 |
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Topics: Consensus; Humans; Hydrazines; Multiple Myeloma; Practice Guidelines as Topic; Triazoles | 2020 |
XPO1-dependent nuclear export as a target for cancer therapy.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Exportin 1 Protein; Forecasting; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Neoplasm; Triazoles | 2020 |
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles | 2020 |
Selinexor for advanced hematologic malignancies.
Topics: Cell Line, Tumor; Hematologic Neoplasms; Humans; Hydrazines; Triazoles | 2020 |
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Disease Management; Exportin 1 Protein; Hematologic Neoplasms; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Prognosis; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triazoles | 2021 |
The nuclear export protein XPO1 - from biology to targeted therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Exportin 1 Protein; Hematologic Neoplasms; Humans; Hydrazines; Karyopherins; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Topics: Adoptive Transfer; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Triazoles | 2020 |
Overview of Ocular Side Effects of Selinexor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Retrospective Studies; Triazoles | 2021 |
Selinexor for the treatment of patients with previously treated multiple myeloma.
Topics: Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Topics: Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Multicenter Studies as Topic; Neutropenia; Treatment Outcome; Triazoles | 2021 |
Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Hydrazines; Infections; Multiple Myeloma; Recurrence; Triazoles | 2021 |
The 'comeback' of Selinexor: From toxic to tolerable.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2022 |
How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepines; Consolidation Chemotherapy; Humans; Hydrazines; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Radiotherapy; Receptors, Chimeric Antigen; Stem Cell Transplantation; Treatment Failure; Triazoles | 2021 |
A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
Topics: Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Triazoles | 2022 |
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Multiple Myeloma; Triazoles | 2022 |
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Humans; Hydrazines; Karyopherins; Male; Multiple Myeloma; Triazoles | 2023 |
[The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review].
Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Triazoles | 2023 |
43 trial(s) available for triazoles and selinexor
| Article | Year |
|---|---|
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Capsules; Disease Progression; Drug Administration Schedule; Drug Compounding; Fasting; Female; Food-Drug Interactions; Humans; Hydrazines; Male; Middle Aged; New York City; Pharmaceutical Solutions; Postprandial Period; Sarcoma; Soft Tissue Neoplasms; Tablets; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Young Adult | 2016 |
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Line, Tumor; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Mice; Multiple Myeloma; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Survival Rate; Topoisomerase II Inhibitors; Triazoles; Tumor Burden | 2016 |
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Topics: Adult; Blast Crisis; Bone Marrow Cells; Disease-Free Survival; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Triazoles | 2017 |
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Topics: Animals; Apoptosis; Blood Platelets; Bone Marrow; Cell Count; Cell Differentiation; Dose-Response Relationship, Drug; Fetus; Hydrazines; Liver; Megakaryocytes; Mice, Knockout; Platelet Activation; Signal Transduction; Stem Cells; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Triazoles | 2017 |
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Receptors, Cytoplasmic and Nuclear; Triazoles | 2018 |
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Androstenes; Benzamides; Humans; Hydrazines; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Triazoles | 2018 |
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Rate; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Recurrence; Retreatment; Treatment Outcome; Triazoles | 2019 |
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Galectins; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; T-Lymphocyte Subsets; Treatment Failure; Triazoles | 2019 |
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Intention to Treat Analysis; Karyopherins; Male; Middle Aged; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Analysis; Thrombocytopenia; Triazoles; Young Adult | 2019 |
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2020 |
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles | 2020 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Triazoles | 2020 |
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hydrazines; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Survival Rate; Triazoles | 2020 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles | 2021 |
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydrazines; Ifosfamide; Lymphoma, T-Cell; Neoplasm Recurrence, Local; Triazoles | 2021 |
A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Non-Randomized Controlled Trials as Topic; Prognosis; Sarcoma; Tissue Distribution; Triazoles | 2021 |
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Mice; Prednisone; Rituximab; Triazoles; Vincristine | 2021 |
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Cancer Pain; Cross-Over Studies; Female; Humans; Hydrazines; Liposarcoma; Male; Middle Aged; Neoplasm Staging; Placebos; Quality of Life; Triazoles | 2021 |
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptors, Cytoplasmic and Nuclear; Topotecan; Triazoles | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytogenetic Analysis; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Treatment Outcome; Triazoles; Young Adult | 2021 |
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Triazoles | 2021 |
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Topics: Age Factors; Aged; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Triazoles | 2021 |
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Triazoles | 2021 |
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Topics: Adult; Aged; Anorexia; Antiemetics; Female; Humans; Hydrazines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Triazoles; Vomiting; Young Adult | 2022 |
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; Translocation, Genetic; Treatment Outcome; Triazoles | 2022 |
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles | 2022 |
Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
Topics: Adult; Aged; Humans; Hydrazines; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Systematic Reviews as Topic; Triazoles | 2021 |
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Topics: Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Triazoles | 2022 |
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Multiple Myeloma; Proteasome Inhibitors; Triazoles | 2022 |
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Child; Double-Blind Method; Humans; Hydrazines; Liposarcoma; Triazoles | 2022 |
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Triazoles | 2022 |
Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Topics: Active Transport, Cell Nucleus; Humans; Hydrazines; Neoadjuvant Therapy; Rectal Neoplasms; Triazoles | 2022 |
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HOR
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Melphalan; Multiple Myeloma; Triazoles | 2022 |
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Hydrazines; Prospective Studies; Triazoles | 2023 |
129 other study(ies) available for triazoles and selinexor
| Article | Year |
|---|---|
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Topics: Adult; Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Proliferation; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drug Evaluation, Preclinical; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Chaperones; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Transport; Receptors, Cytoplasmic and Nuclear; Ribonucleoproteins; Transcription Factors; Triazoles | 2013 |
Redirecting traffic using the XPO1 police.
Topics: Animals; Antineoplastic Agents; Exportin 1 Protein; Gene Expression Regulation, Leukemic; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2013 |
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.
Topics: B-Lymphocytes; Cell Movement; Cell Proliferation; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Triazoles | 2014 |
KPT-330 has antitumour activity against non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Exportin 1 Protein; G1 Phase; Genes, p53; Humans; Hydrazines; Karyopherins; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2014 |
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Liver Neoplasms; Mice; Mice, Nude; Oncogene Proteins; Proto-Oncogene Proteins; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.
Topics: Active Transport, Cell Nucleus; Animals; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase 4; Cysts; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Mice; Polycystic Kidney, Autosomal Dominant; Receptors, Cytoplasmic and Nuclear; Triazoles; TRPP Cation Channels | 2014 |
SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Receptors, Cytoplasmic and Nuclear; Translational Research, Biomedical; Triazoles | 2014 |
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Male; Mice, SCID; Neoplasm Metastasis; Osteoblasts; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Exportin 1 Protein; Glioblastoma; Humans; Hydrazines; Karyopherins; Macaca fascicularis; Male; Mice; Oxadiazoles; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiazoles; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Animals; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Approval; Drug Resistance, Neoplasm; Epithelial Cells; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Kidney Neoplasms; Male; Mice, Nude; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Triazoles; United States; United States Food and Drug Administration; Xenograft Model Antitumor Assays | 2014 |
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Topics: Active Transport, Cell Nucleus; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Gene Library; Humans; Hydrazines; Imatinib Mesylate; K562 Cells; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Signal Transduction; Triazoles; Tumor Stem Cell Assay | 2015 |
Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle Checkpoints; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Delivery Systems; Exportin 1 Protein; Homologous Recombination; Humans; Hydrazines; Jurkat Cells; Karyopherins; Kinetics; Mutation; Protein Binding; Receptors, Cytoplasmic and Nuclear; Triazoles | 2015 |
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Pyrazoles; Pyrimidines; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Hydrazines; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Exportin 1 Protein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazines; Inhibitor of Apoptosis Proteins; Karyopherins; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, SCID; Neoplasm Proteins; Oxadiazoles; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Survivin; Thiazoles; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
Topics: Animals; Exportin 1 Protein; Humans; Hydrazines; Immunosuppression Therapy; Karyopherins; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Exportin 1 Protein; Female; Humans; Hydrazines; Inhibitory Concentration 50; Karyopherins; Mice; Mice, SCID; Neoplasms, Experimental; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Cycle; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Cell Tracking; Fluorescent Dyes; Humans; Hydrazines; Phenotype; Single-Cell Analysis; Triazoles | 2015 |
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Topics: Acrylates; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epithelial-Mesenchymal Transition; Exportin 1 Protein; Fatty Acids, Unsaturated; Humans; Hydrazines; Karyopherins; MCF-7 Cells; Receptors, Cytoplasmic and Nuclear; Snail Family Transcription Factors; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2015 |
XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Exportin 1 Protein; Humans; Hydrazines; Inhibitor of Apoptosis Proteins; Karyopherins; Mice; Radiation; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Cytoplasmic and Nuclear; Rectal Neoplasms; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Topics: Adult; Analgesics; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Grading; Oxadiazoles; Prostatic Neoplasms; Survivin; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 10; Caspase 8; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Enzyme Activation; Humans; Hydrazines; Intracellular Space; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Triazoles; Xenograft Model Antitumor Assays | 2016 |
A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Topics: Acrylamides; Acrylates; Active Transport, Cell Nucleus; Animals; Antibiotics, Antineoplastic; Biotinylation; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cells, Cultured; Drug Evaluation, Preclinical; Exportin 1 Protein; Fatty Acids, Unsaturated; HCT116 Cells; Humans; Hydrazines; Karyopherins; Leukocytes, Mononuclear; Mice; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Reproducibility of Results; Thiazoles; Triazoles | 2016 |
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Crizotinib; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Hydrazines; Lymphoma, Large-Cell, Anaplastic; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Nucleophosmin; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; RNA Interference; Signal Transduction; Transplantation, Heterologous; Triazoles | 2016 |
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Exportin 1 Protein; Female; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazines; Karyopherins; Mice, Nude; Proto-Oncogene Proteins c-kit; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2016 |
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Exportin 1 Protein; Female; Gene Knockdown Techniques; Humans; Hydrazines; Imidazoles; Immunoblotting; Immunohistochemistry; Insulin-Like Growth Factor I; Karyopherins; Mice; Mice, Nude; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Pyrazines; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA-Binding Protein EWS; Sarcoma, Ewing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2016 |
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blast Crisis; Carcinogenesis; Exportin 1 Protein; Hematopoietic Stem Cells; Heterografts; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Receptors, Cytoplasmic and Nuclear; Triazoles | 2017 |
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Topics: Acrylates; Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Biomarkers; Cell Line, Tumor; Exportin 1 Protein; Female; Gene Expression Profiling; Hodgkin Disease; Humans; Hydrazines; Karyopherins; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Mutation; Receptors, Cytoplasmic and Nuclear; Sequence Analysis, DNA; Triazoles; Young Adult | 2016 |
Integrated genetic and pharmacologic interrogation of rare cancers.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; CRISPR-Cas Systems; Cyclin-Dependent Kinase 4; Doxorubicin; Drug Screening Assays, Antitumor; Exome; Exportin 1 Protein; Female; Genomics; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Piperazines; Pyridines; Rare Diseases; Receptors, Cytoplasmic and Nuclear; RNA Interference; Sarcoma; Sequence Analysis, RNA; Triazoles | 2016 |
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Proto-Oncogene Proteins c-myc; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Topoisomerase II Inhibitors; Triazoles | 2016 |
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Everolimus; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Mice, Inbred ICR; Mice, SCID; Oxadiazoles; Prednisone; Protein Kinase Inhibitors; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA; Triazoles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays | 2016 |
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Cell Death; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Fibrosarcoma; Humans; Hydrazines; Karyopherins; Mice, Inbred ICR; Mice, SCID; NF-kappa B; NF-KappaB Inhibitor alpha; Osteosarcoma; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Signal Transduction; Time Factors; Transcription Factor RelA; Transfection; Triazoles | 2016 |
[Radiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Exportin 1 Protein; Hydrazines; Karyopherins; Mice; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Cytoplasmic and Nuclear; Rectal Neoplasms; Treatment Outcome; Triazoles | 2016 |
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Targeting Cancer at the Nuclear Pore.
Topics: Animals; Antineoplastic Agents; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Neoplasms; Nuclear Pore; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinase B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Insulin-Like Growth Factor Binding Protein 5; Karyopherins; Liposarcoma; Male; Mice; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Cytoplasmic and Nuclear; Receptors, Somatomedin; RNA Interference; Signal Transduction; Time Factors; Transfection; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cell Survival; Colorectal Neoplasms; Drug Synergism; HCT116 Cells; HeLa Cells; Humans; Hydrazines; Mice; Proteasome Inhibitors; Triazoles; Tumor Suppressor Protein p53; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; CTLA-4 Antigen; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Exportin 1 Protein; Humans; Hydrazines; Immunomodulation; Karyopherins; Melanoma, Experimental; Mice; Neoplasms; Receptors, Cytoplasmic and Nuclear; T-Lymphocytes; Triazoles | 2017 |
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Survival; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Karyopherins; Mice; NF-kappa B; Oligopeptides; Receptors, Cytoplasmic and Nuclear; Sarcoma; Survivin; Transcription Factor RelA; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.
Topics: Apoptosis; Chromosomes, Human, Pair 2; Drug Resistance, Neoplasm; Exportin 1 Protein; Gene Expression Regulation, Leukemic; Humans; Hydrazines; Karyopherins; Leukemia, Lymphocytic, Chronic, B-Cell; Receptors, Cytoplasmic and Nuclear; Triazoles | 2017 |
Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Protein Binding; Receptors, Cytoplasmic and Nuclear; Triazoles | 2017 |
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Doxorubicin; Female; Furans; Humans; Hydrazines; Ketones; MCF-7 Cells; Mice; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms, Glandular and Epithelial; Random Allocation; Receptors, Cytoplasmic and Nuclear; Thymus Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Disease Models, Animal; Doxorubicin; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Models, Biological; Neoplasm Transplantation; Receptors, Cytoplasmic and Nuclear; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2017 |
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Exportin 1 Protein; Female; Forkhead Box Protein O1; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Ovarian Neoplasms; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Compassionate Use Trials; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Middle Aged; Salvage Therapy; Triazoles | 2018 |
Selinexor and dexamethasone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles | 2018 |
The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
Topics: Animals; Brain Neoplasms; Female; Glioblastoma; Humans; Hydrazines; Mice; Mice, Nude; Radiation Tolerance; Triazoles | 2018 |
Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Lineage; Cell Survival; Exportin 1 Protein; G1 Phase; Humans; Hydrazines; Imidazoles; Karyopherins; Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Suppressor Protein p53 | 2018 |
KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Exportin 1 Protein; Hydrazines; Karyopherins; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Shock, Septic; Structure-Activity Relationship; Triazoles | 2018 |
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Topics: Active Transport, Cell Nucleus; Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Female; Humans; Hydrazines; Male; Mice; Stomach Neoplasms; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Topics: Aged; Animals; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Down-Regulation; Exportin 1 Protein; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mutation; Nuclear Proteins; Nucleophosmin; Proteolysis; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Promising new treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Hydrazines; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2018 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Karyopherins; Lymphoma, Mantle-Cell; NF-kappa B; Piperidines; Protein Subunits; Pyrazoles; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Triazoles | 2018 |
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Topics: Adult; Aged; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles | 2018 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2019 |
XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Synergism; Eukaryotic Initiation Factor-4F; Exportin 1 Protein; Humans; Hydrazines; Isoquinolines; Karyopherins; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Receptors, Cytoplasmic and Nuclear; RNA, Ribosomal; Triazoles | 2019 |
Selinexor-dexamethasone for refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Hydrazines; Multicenter Studies as Topic; Multiple Myeloma; Retreatment; Triazoles | 2019 |
Responses to selinexor in multiple myeloma.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Selinexor for Refractory Multiple Myeloma.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Selinexor for Refractory Multiple Myeloma. Reply.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Exportin 1 Protein; Female; Follow-Up Studies; HT29 Cells; Humans; Hydrazines; Karyopherins; Ki-67 Antigen; Lymphatic Metastasis; Male; Middle Aged; NF-kappa B; Prognosis; Receptors, Cytoplasmic and Nuclear; Triazoles; Young Adult | 2019 |
Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2020 |
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
Topics: Advisory Committees; Drug Approval; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States; United States Food and Drug Administration | 2020 |
Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
Topics: Humans; Hydrazines; Multiple Myeloma; Quality of Life; Survival Analysis; Triazoles | 2020 |
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Topics: Aged; Antineoplastic Agents; Appetite; Clinical Trials as Topic; Diarrhea; Fatigue; Female; Humans; Hydrazines; Hyponatremia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia; Triazoles | 2020 |
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
Topics: Adult; Aged; Cell- and Tissue-Based Therapy; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; Triazoles | 2020 |
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
Topics: Amino Acid Sequence; Animals; Colitis; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Discovery; Exportin 1 Protein; HEK293 Cells; Humans; Hydrazines; Karyopherins; Male; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Triazoles | 2020 |
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazines; Multiple Myeloma; Precision Medicine; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2020 |
Selective inhibitors of nuclear export in aggressive B-cell lymphomas.
Topics: Active Transport, Cell Nucleus; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Triazoles | 2020 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Macrophages; Mice; Mice, Nude; Piperidines; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Selinexor-associated hyponatremia: single-center, real-world data.
Topics: Humans; Hydrazines; Hyponatremia; Triazoles | 2020 |
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Fatty Acid Desaturases; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Liposarcoma; Oligopeptides; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Triazoles | 2020 |
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact.
Topics: Artifacts; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Triazoles | 2020 |
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact - Authors' reply.
Topics: Artifacts; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Triazoles | 2020 |
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Topics: Antibodies, Bispecific; Cell Line, Tumor; Female; Humans; Hydrazines; Triazoles; Triple Negative Breast Neoplasms | 2020 |
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Fanconi Anemia Complementation Group D2 Protein; Humans; Hydrazines; Karyopherins; Melphalan; Mice, Inbred NOD; Multiple Myeloma; Nestin; Receptors, Cytoplasmic and Nuclear; Triazoles; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.
Topics: Adenosine Monophosphate; Adoptive Transfer; Alanine; Antibodies, Viral; Antiviral Agents; Broadly Neutralizing Antibodies; Cell- and Tissue-Based Therapy; COVID-19; COVID-19 Drug Treatment; Humans; Hydrazines; Killer Cells, Natural; Models, Theoretical; SARS-CoV-2; Time Factors; Treatment Outcome; Triazoles; Viral Load; Virus Shedding | 2020 |
Targeting the expression of T antigens with selinexor (KPT-330) shows promise for Merkel cell polyomavirus-positive Merkel cell carcinoma treatment.
Topics: Antigens, Viral, Tumor; Carcinoma, Merkel Cell; Humans; Hydrazines; Merkel cell polyomavirus; Polyomavirus Infections; Skin Neoplasms; Triazoles; Tumor Virus Infections | 2021 |
XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Topics: Active Transport, Cell Nucleus; Animals; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cytoplasm; Drug Synergism; Exportin 1 Protein; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Lung Neoplasms; Mice; Phthalazines; Receptors, Cytoplasmic and Nuclear; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Choline; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Combinations; Drug Synergism; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Phthalazines; Piperazines; Random Allocation; Receptors, Cytoplasmic and Nuclear; S Phase Cell Cycle Checkpoints; Salicylates; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.
Topics: Active Transport, Cell Nucleus; Humans; Hydrazines; Nerve Sheath Neoplasms; Neurofibrosarcoma; Triazoles | 2021 |
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Leukemia-Lymphoma, Adult T-Cell; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Suppressor Protein p53 | 2021 |
KPT-330 Prevents Aortic Valve Calcification via a Novel C/EBPβ Signaling Pathway.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Axin Protein; Calcinosis; CCAAT-Binding Factor; Drug Repositioning; Exportin 1 Protein; Hydrazines; Karyopherins; Klotho Proteins; Mice; Receptors, Cytoplasmic and Nuclear; Triazoles; Wnt Signaling Pathway | 2021 |
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Dedifferentiation; Cell Nucleus; Down-Regulation; Doxorubicin; Humans; Hydrazines; Liposarcoma; Male; Mice; Mice, Nude; Random Allocation; Survivin; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis.
Topics: Humans; Hydrazines; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Recurrence; Triazoles | 2021 |
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles | 2021 |
Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Studies as Topic; Female; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Triazoles; Young Adult | 2021 |
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Triazoles | 2021 |
Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
Topics: Apoptosis; Bone Neoplasms; Carcinoma, Hepatocellular; Cell Proliferation; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Hypoxia-Inducible Factor 1, alpha Subunit; Karyopherins; Liver Neoplasms; Osteosarcoma; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured | 2021 |
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles | 2021 |
Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug-Drug Interactions of Selinexor with Posaconazole in Rats.
Topics: Animals; Chromatography, High Pressure Liquid; Hydrazines; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Triazoles | 2021 |
Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
Topics: Amyotrophic Lateral Sclerosis; Antineoplastic Agents; Cell Line, Tumor; Exportin 1 Protein; Glioblastoma; Humans; Hydrazines; Karyopherins; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States | 2021 |
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
Topics: Bortezomib; Boston; Control Groups; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2021 |
Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Hydrazines; Linear Models; Mice; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2021 |
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triazoles | 2021 |
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Topics: Active Transport, Cell Nucleus; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cytokines; Exportin 1 Protein; Ferrets; Humans; Hydrazines; Karyopherins; Receptors, Cytoplasmic and Nuclear; Respiratory System; SARS-CoV-2; Triazoles; Tumor Suppressor Proteins; Vero Cells; Virus Replication | 2021 |
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
Topics: Active Transport, Cell Nucleus; Antigens, CD19; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Combined Modality Therapy; Cytoplasm; Exportin 1 Protein; Humans; Hydrazines; Immunotherapy, Adoptive; Karyopherins; Neoplasms; Receptors, Chimeric Antigen; Receptors, Cytoplasmic and Nuclear; STAT3 Transcription Factor; Time Factors; Triazoles | 2021 |
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Boston; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma.
Topics: Acute Kidney Injury; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Lysis Syndrome | 2021 |
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
Topics: Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles | 2021 |
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Treatment Outcome; Triazoles | 2022 |
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Triazoles | 2021 |
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Female; High-Throughput Screening Assays; Humans; Hydrazines; Mice; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Triazoles | 2021 |
ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.
Topics: Adenosine Deaminase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Transformation, Neoplastic; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazines; Interferon-gamma; Male; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Knockout; Necroptosis; Pyroptosis; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Signal Transduction; Skin Neoplasms; Triazoles | 2021 |
Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Cells, Cultured | 2022 |
[New European approval: Selinexor for triple class refractory multiple myeloma].
Topics: Administration, Oral; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Europe; Humans; Hydrazines; Immunomodulating Agents; Membrane Glycoproteins; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Triazoles | 2022 |
Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydrazines; Mice; Mice, Nude; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2022 |
Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma.
Topics: Carcinoma, Merkel Cell; DNA Damage; Humans; Hydrazines; Merkel cell polyomavirus; Skin Neoplasms; Triazoles | 2022 |
Combining selinexor with alisertib to target the p53 pathway in neuroblastoma.
Topics: Animals; Apoptosis; Azepines; Cell Line, Tumor; Humans; Hydrazines; Karyopherins; Mice; Neuroblastoma; Proteomics; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2022 |
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Retrospective Studies; Triazoles | 2022 |
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consensus; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2022 |
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Karyopherins; Multidrug Resistance-Associated Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Triazoles | 2022 |
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hydrazines; Leukemia, Myeloid, Acute; Proteome; Proto-Oncogene Proteins c-akt; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Exportin 1 Protein; Gallbladder Neoplasms; Hydrazines; Karyopherins; Mice; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; TOR Serine-Threonine Kinases; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1-mediated nuclear export.
Topics: Active Transport, Cell Nucleus; Cell Nucleus; HIV-1; Hydrazines; Karyopherins; Triazoles | 2022 |
Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.
Topics: Apoptosis; Cell Line, Tumor; Humans; Karyopherins; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Triazoles | 2023 |
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.
Topics: Carcinoma, Acinar Cell; Humans; Hydrazines; Salivary Gland Neoplasms; Triazoles | 2023 |
Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?
Topics: Endometrial Neoplasms; Female; Humans; Hydrazines; Neoplasm Recurrence, Local; Triazoles; Tumor Suppressor Protein p53 | 2023 |